How to appeal a Humana glaucoma (drops + procedures + surgery) denial

The framework that applies to your appeal

Medicare Advantage plans follow a separate appeal track from commercial plans. Reconsideration must be requested within 60 days; if the plan misses its deadline, the case auto-forwards to the IRE (Maximus).

Humana-specific note: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.

What Humana's policy requires for glaucoma (drops + procedures + surgery)

Cited policy: Humana Coverage of iDose TR (Travoprost Intracameral Implant)

POAG or OHT. Documented inadequate response or intolerance to topical PGA / Vyzulta / Rhopressa OR documented adherence barriers (tremor, dexterity, cognitive). Open angle. Endothelial cell density adequate (>2,000 cells/mm²). Single administration; redosing per FDA label update 2025.

How Humana denies glaucoma (drops + procedures + surgery) — and how to counter it

Where Humana pushes back: 1) iDose TR experimental; 2) Try drops longer first; 3) Citing CyPass precedent.

Counter-arguments that hold up: iDose TR FDA-approved Dec 13 2023 — NOT experimental. Pivotal Phase 3 GC-010 + GC-012 (1,150 subjects, 89 sites) met primary efficacy endpoints at 3 mo; 93% slow-release iDose TR remained well-controlled at 12 mo vs 67% timolol; 81% medication-free at 12 mo. Glaukos titanium implant designed to NOT migrate into corneal endothelium — distinct from withdrawn CyPass design. CyPass withdrawal (Aug 2018) was post-market surveillance based on COMPASS-XT 60-mo ECL data — does NOT apply to titanium-implant iDose TR or to other MIGS with different mechanisms. Patient has documented drop adherence barrier / OSD / inadequate IOP control.

What Humana typically denies for glaucoma (drops + procedures + surgery)

Across Humana's commercial and Medicare books, denials cluster around a small number of patterns. For glaucoma (drops + procedures + surgery), expect:

• MA plan step therapy on Part B drugs
• Skilled nursing facility days
• Prior auth on specialty drugs
• OON emergency reduction

Treatments most often denied in this category

These are the glaucoma (drops + procedures + surgery) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Latanoprost (generic)
• Xelpros (BAK-free latanoprost)
• Travatan Z (travoprost)
• Lumigan (bimatoprost)
• Zioptan (tafluprost PF)
• Vyzulta (LBN)

How to submit the appeal to Humana

1. Read the denial letter — note the exact denial reason code and the appeal deadline (60 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Humana cited in the denial.
3. File the appeal through Humana's portal (members: https://www.humana.com ; providers: https://www.humana.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In KY, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Humana's prior-authorization criteria by drug: Humana PA criteria on ApprovalHelp.